Corrigendum to “First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report” [Leukemia Research Reports (2024) Volume 22, 100491]
Saved in:
| Main Authors: | E. Amabile, F. Fazio, M. Martelli, M.T. Petrucci |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Leukemia Research Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048925000019 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report
by: E. Amabile, et al.
Published: (2024-01-01) -
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01) -
Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma
by: Doris K. Hansen, et al.
Published: (2024-11-01) -
Successful Daratumumab, Lenalidomide, and Dexamethasone Treatment of Refractory Type I Cryoglobulinemia From Monoclonal Gammopathy of Undetermined Significance
by: Karen J. Shou, et al.
Published: (2024-11-01) -
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01)